The RNA was DNase treated usingĘAmbionĘTurbo DNase. RNAĐSeqĘlibraries were prepared from theĘDNase-treated RNA using the EpicentreĘScriptSeqĘv2 RNA-SeqĘLibrary Preparation Kit and following 10-15 cycles of amplification, libraries were purified usingĘAMPureĘXP beads. Each library was quantified using Qubit and the size distribution assessed using the Agilent 2100ĘBioanalyser. These final libraries were pooled in equimolar ratios using the Qubit and Bioanalyzer data. The quantity and quality of each pool was assessed by Bioanalyzer and subsequently by qPCR using the Illumina Library Quantification Kit from Kapa on a Roche Light Cycler LC480II according to manufacturer's instructions.Ę The template DNA was denatured according to the protocol described in the Illumina User Guide and loaded at 12ĘpMĘconcentration. To improve sequencing quality control 1%ĘPhiXĘwas spiked-in. The sequencing was carried out on the IlluminaĘHiSeqĘ2500 with version 4 chemistry generating 2 _ 125ĘbpĘpaired end reads.Ę

Illumina HiSeq 2500 paired end sequencing; RNA-seq of Homo sapiens: Acute_Fatal_96

Homo sapiens

In 2014 Western Africa experienced an unanticipated explosion of infections with Ebola virus (EBOV). What distinguishes fatal from non-fatal outcomes remains largely unknown, yet is key to optimising personalised treatment strategies. Here transcriptome data for peripheral blood taken from infected and convalescent, recovering patients, was used to identify early stage host factors that were associated with acutely ill patients that ultimately either survived or succumbed to the disease.

Delineating survival from a fatal outcome in Ebola virus disease in humans

Submitter Supplied Information

Samples